Avui, dijous 7 de maig, el Dipòsit Digital no estarà operatiu per tasques d'actualització. Disculpeu les molèsties.
Hoy, jueves 7 de mayo, el Dipòsit Digital no estará operativo debido a tareas de actualización. Disculpen las molestias.
Today, Thursday, May 7th, the Digital Repository will be unavailable due to a system update.

Fitxers

fimmu-14-1252811.pdf (571.52 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2023-09-27

Llicència de publicació

cc by (c) Penack, Olaf et al., 2023
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/208421

Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.3389/fimmu.2023.1252811

Resum

We investigated >= grade 3 (CTC-AE) organ toxicities for commercial CD19 chimeric antigen receptor T cell (CAR-T cell) products in 492 patients (Axi-Cel; n = 315; Tisa-Cel; n = 177) with Large B-cell Lymphoma in the European Society for Blood and Marrow Transplantation (EBMT) CAR-T registry. The incidence of >= grade 3 organ toxicities during the first 100 days after CAR-T was low and the most frequent were: renal (3.0%), cardiac (2.3%), gastro-intestinal (2.3%) and hepatic (1.8%). The majority occurred within three weeks after CAR-T cell therapy. Overall survival was 83.1% [79.8-86.5; 95% CI] at 3 months and 53.5% [49-58.4; 95% CI] at one year after CAR-T. The most frequent cause of death was tumour progression (85.1%). Non-relapse mortality was 3.1% [2.3-4.1; 95% CI] at 3 months and 5.2% [4.1-6.5; 95% CI] at one year after CAR-T. The most frequent causes of non-relapse mortality were cell-therapy-related toxicities including organ toxicities (6.4% of total deaths) and infections (4.4% of total deaths). Our data demonstrates good safety in the European real-world setting.

Matèries

Limfomes, Receptors cel·lulars

Matèries (anglès)

Lymphomas, Cell receptors

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

PENACK, Olaf, et al. Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party. Frontiers in Immunology. 2023. Vol. 14. ISSN 1664-3224. [consulta: 8 de maig de 2026]. Disponible a: https://hdl.handle.net/2445/208421

Exportar metadades

JSON - METS

Compartir registre